However, defactinib was associated with the highest cell viability of differentiated urothelial cells and the lowest viability of urothelial cancer cells and was therefore identified as the FAK inhibitor with the greatest potential for further studies and as a treatment option following tumour resection in bladder cancer. The gene discussed is PTK2; the disease is urinary bladder cancer.